Protocol Ledger

NCT06422806 · Phase III · RECRUITING

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Interventional Phase III clinical trial protocol NCT06422806 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-09-11 Enrollment: 365 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06422806
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)365 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06422806
Protocol FieldVerified Registry Value
NCT IdentifierNCT06422806
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment365 participants (ESTIMATED)
Registered Start Date2024-09-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI